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Abstract Bone continuously remodels throughout life by
coordinated actions of osteoclasts and osteoblasts. Abnor-
malities in either osteoclast or osteoblast functions lead to
bone disorders. The p38 MAPK pathway has been shown to be
essential in controlling osteoblast differentiation and skele-
togenesis. Although p38a is the most abundant p38 member in
osteoblasts, its specific individual contribution in regulating
postnatal osteoblast activity and bone metabolism is
unknown. To elucidate the specific role of p38a in regulating
osteoblast function and bone homeostasis, we generated mice
lacking p38a in differentiated osteoblasts. Osteoblast-specific
p38a knockout mice were of normal weight and size. Despite
non-significant bone alterations until 5 weeks of age, mutant
mice demonstrated significant and progressive decrease in
bone mineral density from that age. Adult mice deficient in
p38a in osteoblasts displayed a striking reduction in cancel-
lous bone volume at both axial and appendicular skeletal sites.
At 6 months of age, trabecular bone volume was reduced by
62 % in those mice. Mutant mice also exhibited progressive
decrease in cortical thickness of long bones. These abnor-
malities correlated with decreased endocortical and trabecular
bone formation rate and reduced expressions of type 1
collagen, alkaline phosphatase, osteopontin and osteocalcin
whereas bone resorption and osteoclasts remained unaffected.
Finally, osteoblasts lacking p38a showed impaired marker
gene expressions and defective mineralization in vitro. These
findings indicate that p38a is an essential positive regulator of
osteoblast function and postnatal bone formation in vivo.
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Introduction
Bone is a dynamic, highly specialized form of connective
tissue composed of a mineralized extracellular matrix and
three major cell types, i.e., osteoclasts, osteoblasts and
osteocytes, which are essential for its structural, mechani-
cal, and metabolic roles. Bone mass and homeostasis is
controlled by continuous remodeling throughout life [1].
This process is the consequence of two principal cellular
functions, bone resorption and bone formation, which are
conducted by osteoclasts and osteoblasts respectively.
Dysregulation of the equilibrium between resorption and
formation can lead to a variety of bone diseases [1].
Osteoblasts are cells of mesenchymal origin which
rebuild resorbed bone by synthesizing proteins of the bone
matrix and by inducing matrix mineralization. Those bone-
forming cells are also able to regulate osteoclastogenesis
and consecutive bone resorption. In spite of significant
progress in understanding the molecular basis of osteoblast
differentiation during embryonic development, signaling
pathways controlling osteoblast functions in postnatal bone
remodeling are less understood. Among them, the p38a
mitogen-activated protein kinase (MAPK) pathway is
suggested as an important regulator of bone homeostasis.
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The p38 MAPKs belong to the MAPK superfamily and
is composed of four members, i.e., p38a, p38b, p38c, and
p38d [reviewed in 2, 3]. These p38 MAPKs are encoded by
distinct genes and share *60 % of sequence homology.
p38 MAPK activation has been shown to occur in response
to various extracellular stimuli such as stresses, inflam-
matory cytokines and growth factors. Despite similar
activation, differences exist among the four members and
thus each may have highly specific, individual contribu-
tions to biologic events [2, 3]. p38 MAPKs have been
shown to be implicated in proliferation, differentiation,
apoptosis, senescence and cytokine production. p38
MAPKs are activated by MAPK kinase (MKK) 3 and 6 [2,
3]. Several upstream membrane-proximal kinases
(MAP3 K) can activate MKK3 and MKK6 including
TAK1, ASK1, MKKK4, and MLKs [2, 3].
Previous in vitro studies using cell lines or primary
osteoblasts with selective p38 inhibitors have shown that
the p38 MAPK pathway regulates alkaline phosphatase
activity and extracellular matrix mineralization in response
to different osteogenic signals such as BMP-2 [4, 5], TGF-
b [5], epinephrine [6], PTH [7], Wnt proteins [8] and
mechanical stimuli [9]. Moreover, several reports have also
indicated that the p38 pathway regulates the expression and
activation of critical transcription factors implicated in
osteoblastogenesis, i.e., Dlx5, Runx2, and Osx [5, 10–12].
More recently, an in vivo investigation has highlighted
the physiological role of TGF-b-activated kinase 1 (TAK1)
in osteoblastogenesis and bone formation [12]. TAK1 is a
MAP3 K acting downstream of BMP and TGF-b receptors.
Although TAK1 can activate different signaling cascades,
the MKK3/6-p38 pathway has been suggested as the main
mediator of TAK1 function in osteoblasts [12]. Interest-
ingly, p38b knockout mice have been shown to exhibit a
low bone mass phenotype suggesting that loss of p38b is
not compensated by p38a and therefore, that p38a and
p38b may have different functions in bone formation and
development [12]. This hypothesis has been confirmed by
in vitro analyses demonstrating that p38a regulates early
osteoblast differentiation whereas p38b controls late
osteoblast maturation [12]. Another MAP3K, mixed-line-
age kinase 3 (MLK3) acting downstream of faciogenital
dysplasia protein 1, has also been identified as a regulator
of osteoblastogenesis and bone development by modulating
ERK and p38 MAPK pathways [13]. In addition, the
genetic disruption of the neighbor of Brca1 gene-encoding
Nbr1, a receptor for selective autophagosomal degradation
of ubiquitinated target proteins, has been shown to induce
an age-dependent increase in bone mass due to continuous
osteoblastic p38 MAPK activation and subsequent stimu-
lated bone formation [14].
The p38a MAPK is the most abundant p38 member in
bone [12]. Although all these previous reports indicate that
the p38 MAPK pathway is essential for osteoblast differ-
entiation, the specific individual contribution of p38a in
postnatal bone formation remains to be elucidated. To
investigate the role of p38a in regulating postnatal osteo-
blast function and bone homeostasis in vivo, we therefore
generated mice for which the p38a-encoding gene was
specifically disrupted in differentiated osteoblasts after
birth by using Cre-LoxP technology. The bone phenotypes
of control and osteoblast-specific p38a knockout mice were
analyzed and compared at different ages. Osteoblast-spe-
cific excision of p38a led to age-dependent decrease in
bone mass and bone mineral density. This low bone mass
phenotype was observed in axial and appendicular bones. It
was the consequence of defective osteoblast function and
impaired endocortical and trabecular bone formation. Our
results provide the first evidence that the p38a MAPK is a
critical regulator of postnatal osteoblastic bone formation.
Materials and methods
Generation of conditional p38a knockout mice
Mice lacking p38a in osteoblasts were generated by breeding
mice harboring floxed p38a-encoding gene (p38a with LoxP
sites flanking exons 2 and 3; Fig. 1a) [15] with mice
expressing the Cre recombinase under the control of the
osteocalcin promoter (Ocn-Cre) [16]. Ocn-Cre mice, in
which Cre expression exclusively occurs in osteoblasts at
birth [16], represent a unique tool to address postnatal
osteoblast function. Mice homozygous for floxed p38a
alleles (p38af/f) were crossed with Ocn-Cre mice to generate
Ocn-Cre;p38af/? mice. These mice were then crossed with
p38af/f mice to generate Ocn-Cre;p38af/f mice (Dp38a). Cre-
mediated excision of exons 2 and 3, which encode the ATP-
binding site of the p38a kinase domain, has been shown to
result in p38a-null alleles [15, 17]. Dp38a mice were healthy
and fertile and used for subsequent crosses. Mice were
maintained under standard non-barrier conditions, and had
access to mouse diet RM3 containing 1.24 % calcium
and 0.56 % available phosphorus (SDS, Betchworth, UK)
and water ad libitum. Genotyping of the wild-type, floxed,
and excised p38a-encoding gene were carried out by PCR.
All performed experiments were in compliance with the
Ethical Principles and Guidelines for Scientific Experiments
on Animals (2nd edition) and approved by the Ethical
Committee of the University of Geneva School of Medicine
and the State of Geneva Veterinarian Office.
Dual-energy X-ray absorptiometry and l-CT
Mice were anesthetized through intraperitoneal injection of
ketamine/xylazine and placed on a tray in a mouse
3116 C. Thouverey, J. Caverzasio
123
densitometer (PIXImus II, GE Lunar, Madison, WI) for
analysis. Total body, femoral and spinal bone mineral
densities (BMD) were measured in vivo. Mice were then
sacrificed by cervical dislocation and their bones were
excised for micro-computed tomography (lCT) analyses.
Trabecular bone microarchitecture of 5th lumbar vertebral
bodies and distal femurs, and cortical bone geometry of
femoral midshafts were assessed using lCT (micro-CT40,
Scanco Medical AG, Basserdorf, Switzerland). Femurs and
vertebrae were scanned with an isotropic voxel size of
12 lm.
Histological and histomorphometric analysis
To measure dynamic indices of bone formation, 12-week-
old mice received subcutaneous injections of calcein
(10 mg/kg body weight; Sigma) at 9 and 2 days before
euthanasia and bone collection. After dehydration in a
graded ethanol solution series, undecalcified femurs were
embedded in methyl methacrylate (Merck), and 8-lm
transversal sections of midshafts were cut using a MET-
KON Finocut low-speed precision cutter and mounted
unstained for fluorescence evaluation. 5-lm sagittal sec-
tions of distal femurs were cut with a Polycut E microtome
(Leica Corp. Microsystems AG, Glattbrugg, Switzerland)
and mounted unstained for fluorescence visualization or
stained with modified Goldner’s trichrome. Histomorpho-
metric measurements were carried out on the endocortical
and periosteal surfaces of femoral midshaft sections and on
the secondary spongiosa of distal femur sections using a
Leica Q image analyzer at 409 magnification as previously
described [18].
ELISA assays
Sera were collected from 12-week-old mice and tartrate-
resistant acid phosphatase 5b (TRAP5b, a marker of bone
resorption) levels determined by ELISA according to the
manufacturer’s instructions (Immunodiagnostic Systems
Ltd).
Primary osteoblast cultures
Primary osteoblasts were isolated from long bone
metaphyses of 12-week-old control and osteoblast-specific
p38a knockout mice as recently described [19]. Mice were
sacrificed by cervical dislocation and rinsed in 70 % eth-
anol for 5 min. Humeri, tibiae and femurs were dissected
Fig. 1 Disruption of p38a in
osteoblasts leads to decreased
BMD. a Strategy for the
generation of mice with LoxP-
flanked p38a alleles [15]. Exons
2 and 3 which encode the ATP-
binding site of the kinase
domain were flanked by two
LoxP sequences (shown as
black arrowheads). Cre-
mediated deletion produces the
Dp38a allele. b RT-PCR
detection of p38a (576 bp) and
of Dp38a lacking exons 2/3
(387 bp) in tissues from
p38aflox/flox (p38af/f) and Ocn-
Cre;p38aflox/flox mice (Dp38a).
Osteocalcin promoter-driven
deletion of exons 2 and 3 was
only detected in skeletal tissues
of Dp38a mice. c Whole body
BMD of female and male p38af/f
and Dp38a mice at 12 weeks of
age (n = 6 per group).
d Femoral and e lumbar BMD
of female p38af/f and Dp38a
mice at 5, 12 and 26 weeks of
age. **p B 0.01
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and their epiphyses removed. Bone marrow was flushed out
and bone cavities were washed several times with a-MEM
(Amimed, Bioconcept) supplemented with 10 % FBS, 1 %
penicillin/streptomycin and 2.2 g/L L-glutamine (all from
Gibco). Bones were then cut into small chips and incubated
in a-MEM containing 10 % FBS and 1 mg/mL collagenase
II (Sigma) for 90 min on a shaking incubator at 37 C.
Digestion medium and released cells were discarded. Bone
chips were washed several times with medium and incu-
bated in a-MEM containing 10 % FBS at 37 C in a
5 % CO2/95 % air humidified atmosphere for 3 days to
allow osteoblast migration from bone fragments. After
5 days, cell cultures were trypsinized (with trypsin/EDTA
from Sigma) and passaged at a split ratio of 1:3. Bone
fragments and osteoblasts were seeded together for at least
3 additional days. At the second passage, bone chips were
removed. The medium was changed every 2–3 days.
Osteoblasts at passages 3–4 were used for in vitro
experiments.
Proliferation and differentiation assays
To assess osteoblast proliferation, cells were seeded at
40,000 cells/well in 12-well plates with a-MEM containing
10 % FBS and counted after 6 days using a cell counter
(Coulter Counter). For differentiation assays, osteoblasts
that reached confluence were incubated in osteogenic
medium containing a-MEM, 10 % FBS, 0.05 mM
L-ascorbate-2-phosphate (Sigma) and 10 mM b-glycero-
phosphate (AppliChem GmbH). After 10 days, alkaline
phosphatase activity was measured as previously described
[6–8]. After 21 days, matrix mineralization was evaluated
by Alizarin Red-S staining (AR-S; Sigma). To quantify
mineral-bound AR-S, cell cultures were destained with
10 % hexadecylpyridinium chloride (Sigma) and AR-S
concentration was determined by measuring the absor-
bance at 562 nm. In these experiments, the effect of SD-
282, a selective p38a inhibitor (SCIOS, Fremont, CA),
were also tested.
RNA isolation, RT-PCR and real-time PCR
Total RNA was extracted from murine femurs or primary
osteoblasts using peqGOLD TriFastTM (peqlab Biotech-
nologie GmbH) and purified using an RNeasy Mini Kit
(Qiagen) [18]. Single-stranded cDNA was synthesized
from 2 lg of total RNA using a High-Capacity cDNA
Archive Kit (Applied Biosystems) according to the man-
ufacturer’s instructions. RT-PCR, with primers
surrounding p38a exons 2 and 3, was used to check Cre-
mediated excision of those two exons in bones of Dp38a
mice (Fig. 1b). Real-time PCR was performed to measure
the relative mRNA levels using the StepOnePlusTM Real-
Time PCR System with SYBR Green (Applied Biosys-
tems). The primers used in our analyses are indicated in the
supplementary materials (Table S1). The mean mRNA
levels were calculated from triplicate analyses of each
sample. Obtained mRNA level for a gene of interest was
normalized to b2-microglobulin mRNA level in the same
sample.
Statistical analysis
All results were expressed as mean ± standard deviation.
All statistical analyses were performed using the Student’s
t test. Differences were considered as significant when
p \ 0.05.
Results
Generation of mice lacking p38a in osteoblasts
To investigate the role of p38a in regulating postnatal
osteoblast function and bone homeostasis in vivo, we
generated mice lacking p38a in their differentiated osteo-
blasts. Ocn-Cre;p38af/f mice, which were viable and fertile,
were crossed with p38af/f mice to obtain control (p38af/f)
and Ocn-Cre;p38af/f (referred to as Dp38a) littermates with
expected Mendelian ratio. Excision of p38a exons 2 and 3
was checked in different tissues by RT-PCR using primers
surrounding those two exons. A band corresponding to
wild-type p38a (576 bp) was observed in all tissues
whereas a band corresponding to p38a lacking exons 2/3
(387 bp) was only detected in femurs, calvaria and spines
of Dp38a mice showing that Cre-mediated deletion only
occurred in skeletal tissues of Dp38a mice (Fig. 1b).
Low BMD in adult mice lacking p38a in osteoblasts
A longitudinal analysis of bone mineral density was per-
formed by using dual-energy X-ray absorptiometry. Mice
carrying an osteoblast-specific deletion of p38a had normal
body weight and size throughout life (data not shown). At
12 weeks of age, Dp38a mice of both sexes displayed
significant decrease in whole body BMD in comparison to
their control littermates (p \ 0.01; Fig. 1c). BMD was
similarly decreased in both axial and appendicular skeletal
sites at 12 weeks of age (p \ 0.001; Fig. 1d, e). There was
only a non-significant trend at 5 weeks but, then femoral
and lumbar BMD progressively decreased as the animals
aged (Fig. 1d, e). Both femoral and lumbar BMD of
26-week-old female Dp38a mice were significantly
decreased by 19 %.
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Low cortical and trabecular bone mass in adult Dp38a
mice
Bone microarchitecture of p38af/f and Dp38a mice was
evaluated by three-dimensional lCT scanning analyses.
Femoral length and diameter of Dp38a mice were normal
in comparison to those of p38af/f mice. However, Dp38a
mice of both sexes displayed significant alterations of
femoral microarchitecture at 12 weeks of age (supple-
mentary Table S2). Consistent with BMD data, a
longitudinal analysis performed on female mice revealed
non-significant decreases in cortical and trabecular bone
volumes at 5 weeks and then progressive reductions as
the animals aged (p B 0.002; Figs. 2c, 3b). At the fem-
oral midshaft, the total volume and cross-sectional area
remained unchanged between mutant and control mice
(Fig. 2a, b). However, Dp38a adult mice showed
decreased cortical thickness (-20 %, p B 0.0003;
Fig. 2d). In addition, adult mutant mice also displayed
significant reduction in trabecular bone volume
(p B 0.002; Fig. 3b) associated with low trabecular
thickness (p B 0.05; Fig. 3c) at the distal femur.
Decreased trabecular number and increased trabecular
separations became significant at the distal femurs of
26-week-old mutant mice (p = 0.01; Fig. 3d, e). At that
age, femoral trabecular bone volume was reduced by
62 % in Dp38a mice (p = 0.0007; Fig. 3b). A similar
pattern of low trabecular bone mass was observed at the
5th lumbar vertebral body of 12-week-old Dp38a mice
(supplementary Fig. S1).
Low bone formation and unaffected bone resorption
in adult Dp38a mice
Histomorphometric analyses by double calcein labeling
were carried out on femurs of p38af/f and Dp38a mice at
12 weeks of age to measure dynamic indices of bone for-
mation. Mutant mice displayed reduced endocortical and
trabecular mineral apposition rate (MAR), mineralizing
surfaces (MS/BS) and bone formation rate (BFR)
(Table 1). Those reductions were more pronounced in
trabecular bone sites (Table 1). Furthermore, periosteal
MAR was slightly decreased in Dp38a mice but MS/BS
and BFR were not significantly reduced at periosteal bone
surfaces (Table 1). Even though mutant mice showed
striking reduction of bone formation in trabecular bone
(Fig. 4a, b), static histomorphometric analyses did not
reveal significant changes in number of osteoblasts lining
trabecular bone surfaces (Fig. 4c, d). However, functional
defects of osteoblasts could be explained by significant
lower expressions of type 1 collagen (Col1a1; -45 %;
p = 0.05), alkaline phosphatase (Alp; -50 %; p = 0.02),
osteopontin (Opn; -64 %; p = 0.05) and osteocalcin
(Ocn; -56 %; p = 0.005) (Fig. 4e) in the long bone of
Dp38a mice. Nevertheless, expression of the master regu-
lator of osteoblast development, i.e., Runx2, remained
unchanged between control and mutant mice (Fig. 4e).
These data demonstrated an impaired bone formation by
osteoblasts lacking p38a.
Furthermore, ex vivo gene expression analyses also
revealed a reduction of both rank ligand (Rankl) and
Fig. 2 Mice lacking p38a in
their osteoblasts exhibit low
cortical bone mass.
a Representative reconstructed
lCT images of femoral
midshafts from 12-week-old
female p38af/f versus Dp38a
mice. b–d Cortical bone
microarchitecture was measured
at femoral midshaft of female
p38af/f and Dp38a mice at 5
(n = 4 per genotype), 12 (n = 6
per genotype) and 26 (n = 4 per
genotype) weeks of age. lCT
parameters include b TV total
volume, c BV bone volume and
d Ct.Th. cortical thickness.
**p B 0.01
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osteoprotegerin (Opg) expressions (Fig. 5a) in the long
bone of Dp38a mice. However, these effects were not
significant and the relative Rankl/Opg ratio was not
significantly changed (Fig. 5a). Consistent with this
observation, the number of mature osteoclasts covering
trabecular bone surfaces and serum TRAP5b levels
Fig. 3 Mice lacking p38a in
their osteoblasts have low
trabecular bone mass.
a Representative reconstructed
lCT images of distal femurs
from 12-week-old female
p38af/f versus Dp38a mice.
b–e Trabecular bone
microarchitecture was measured
at distal femur of female p38af/f
and Dp38a mice at 5 (n = 4 per
genotype), 12 (n = 6 per
genotype) and 26 (n = 4 per
genotype) weeks of age. lCT
parameters include b BV/TV
bone volume/total volume,
c Tb.Th. trabecular thickness,
d Tb.N. trabecular number,
e Tb.Sp. trabecular separation.
*p \ 0.05, **p B 0.01
Table 1 Bone formation indices from 12-week-old p38af/f and Dp38a female mice
Parameters p38af/f Dp38a p values D (%)
Periosteal Ps-MAR (lm/d) 1.23 ± 0.10 1.06 ± 0.10 0.009 -13.80
Ps-MPm/BPm (%) 42.1 ± 16.6 39.3 ± 9.3 0.71 –
Ps-BFR/BPm (lm/d) 0.52 ± 0.21 0.42 ± 0.12 0.30 –
Endocortical Ec-MAR (lm/d) 1.21 ± 0.13 0.93 ± 0.15 0.007 -23.10
Ec-MPm/BPm (%) 42.2 ± 5.7 31.1 ± 5.6 0.005 -26.30
Ec-BFR/BPm (lm/d) 0.51 ± 0.07 0.29 ± 0.07 0.0002 -43.10
Trabecular Tb-MAR (lm/d) 1.03 ± 0.07 0.76 ± 0.10 0.001 -26.20
Tb-MS/BS (%) 53.8 ± 11.0 34.6 ± 13.4 0.03 -35.70
Tb-BFR/BS (lm/d) 0.55 ± 0.12 0.26 ± 0.10 0.002 -52.70
Dynamic histomorphometric analyses were performed at femoral diaphyses (periosteal and endocortical) and distal femurs (trabecular) of control
(p38af/f) and mutant (Dp38a) female mice (n = 6 per group)
Data are expressed as mean ± SD. p values were determined using unpaired t tests. Significant differences are expressed as percentage
MAR mineral apposition rate, MPm mineralizing perimeter, BPm bone perimeter, MS mineralizing surface, BS bone surface, BFR bone formation
rate
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remained unchanged between control and mutant mice
(Fig. 5b–d). These results indicated that loss of p38a did
not affect osteoclasts and bone resorption.
Suppressed marker expressions and mineralization
in osteoblasts lacking p38a
To further explore the cellular mechanism explaining the
low bone mass of osteoblast-specific p38a knockout mice,
the phenotype of p38a knockout osteoblasts were analyzed
in vitro. In cultures, osteocalcin promoter-driven deletion
of p38a started 2 or 3 days after Dp38a osteoblasts reached
confluence and was maximal after approximately 7 days.
At that time-point, expression was reduced by 65 % in
cultures of Dp38a osteoblasts compared with those of
p38af/f osteoblasts (p = 0.0001; Fig. 6a). Interestingly,
p38a deletion was not compensated by overexpression of
genes encoding p38b, p38c, and p38d (supplementary Fig.
S2). Cell counting performed after confluence did not
reveal changes in number of Dp38a osteoblasts compared
with p38af/f osteoblasts (results not shown). This result was
confirmed with the use of SD282, a selective p38a inhib-
itor, in growing wild-type osteoblast cultures (Fig. 6e),
indicating that the p38a MAPK pathway did not affect
osteoblast proliferation. Osteoblast phenotype was first
evaluated using quantitative real-time PCR. Expression of
Runx2 was not affected by p38a deletion whereas mRNA
expression levels of Col1a1, Alp, Opn and Ocn were sig-
nificantly decreased in Dp38a osteoblasts (-54, -60, -39
and -50 % respectively; Fig. 6a). Moreover, alkaline
phosphatase (ALP) activity was significantly reduced in
Dp38a osteoblast cultures (p = 0.0001; Fig. 6b). Consis-
tent with this observation, SD282 dose-dependently
inhibited basal, TGFb1- and BMP2-induced ALP activity
and mineralization (Fig. 6f; supplementary Fig. S3).
Finally, in vitro matrix mineralization was almost sup-
pressed in Dp38a osteoblast cultures, as shown by alizarin
red staining (p = 0.0001; Fig. 6c, d). Those results clearly
showed that p38a is a positive regulator of osteoblast
function and that loss of p38a could not be compensated by
other p38 members.
Discussion
Postnatal bone remodeling requires an accurate balance
between bone resorption by osteoclasts and bone formation
by osteoblasts [1]. Dysregulations of osteoclast and
osteoblast activities are associated with a range of patho-
logical diseases such as osteoporosis which is characterized
by low bone mass and microarchitectural deterioration of
bone tissue, with a consequent increase in bone fragility
[20, 21]. Due to the increasing need for anabolic therapies
to prevent age-related bone loss, research has been focused
over the last decade on molecular mechanisms regulating
osteoblast function in postnatal remodeling [20–22]. For
instance, Runx2 and Osx have been found to regulate
osteoblast function in adult bone in addition to their pri-
marily established role in osteoblastogenesis [23, 24].
Another transcription factor, Atf4 regulates bone matrix
deposition by mature osteoblasts [25]. Furthermore, several
signaling pathways have been shown to regulate postnatal
osteoblast function including Ihh [26], Wnt/Lrp5 [27],
TGFb-BMP/Smads [28–30], BMP/MEKK2/MEK5-7/Jnk
[31], b-adrenergic [32], IGF-1 [16], insulin [33] and PTH
signaling [34].
The p38 MAPK pathway has been recently shown to be
an essential regulator of osteoblastogenesis during skele-
togenesis [12, 13]. Indeed, mice lacking MKK3 and MKK6
(upstream activators of p38 MAPK) exhibited low bone
mass phenotype at 3 weeks of age, due to impaired
Fig. 4 Osteoblast-specific disruption of p38a decreases bone forma-
tion in mice. a–d Quantitative histomorphometric measurements were
performed on the spongiosa at distal femurs of 12-week-old female
p38af/f and Dp38a mice (n = 6 per group). a MAR mineral apposition
rate; b BFR bone formation rate; c ObS/BS osteoblast surface/bone
surface; d ObN/BPm osteoblast number/bone perimeter. e Real-time
PCR analyses of osteoblast marker gene expression in femurs of
12-week-old female p38af/f and Dp38a mice (n = 6 per group).
*p \ 0.05, **p B 0.01
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osteoblast differentiation and reduced bone formation [12].
Mice lacking p38b also displayed low bone mass since
p38b knockout osteoblasts failed to differentiate into
mature osteoblasts [12]. However, the physiological role of
the p38 MAPK pathway in regulating postnatal bone for-
mation remained to be investigated.
Since p38a is the most abundant p38 member in bone
and osteoblasts [12], the present work aimed to elucidate
its individual contribution in regulating postnatal osteoblast
function. Therefore, we used mice in which p38a was
specifically deleted in osteoblasts by postnatal Cre
recombination under the control of the osteocalcin pro-
moter. Mice lacking p38a in their differentiated osteoblasts
had normal size and weight, and did not show any signif-
icant bone abnormalities before 5–6 weeks of age,
indicating that p38a MAPK in osteoblasts does not regulate
radial bone growth and bone modeling, two active and
predominant processes during mouse growth [35]. How-
ever mutant mice started to exhibit dramatic and
progressive decrease in BMD and bone microarchitectural
alterations from that age. These effects were observed in
both axial and appendicular skeletons of both sexes
(Fig. 1c–e). Cortical thickness that gives strength to long
bones was reduced by 20 % in adult mutant mice whereas
cross-sectional area remained unaffected (Fig. 2). This
observation correlated well with reduced endosteal MAR,
MS/BS and BFR while those parameters were not (or
slightly) changed at periosteal surfaces (Table 1). The most
striking effect observed in adult Dp38a mice was the dra-
matic and age-dependent reductions in trabecular bone
volume and trabecular thickness (Fig. 3). For instance,
trabecular bone volume was decreased by 62 % at the
distal femur of 26-week-old mutant mice (Fig. 3b). This
was associated with an important decrease in trabecular
bone formation (Fig. 4a, b). Decreased bone formation was
not explained by changes in osteoblast number (Fig. 4c, d)
but rather by impaired osteoblast function since Col1a1,
Alp, Opn and Ocn expressions were reduced in the long
bones of mutant mice (Fig. 4e). The osteoblast-specific
deletion of p38a did not affect osteoclast number and
activity in bones (Fig. 5), indicating that p38a is not
required for osteoblast-mediated control of osteoclasto-
genesis and bone resorption, consistent with previous
findings [12]. Mice lacking p38a clearly displayed an age-
dependent osteoporotic phenotype. This low bone mass
phenotype occured when bone remodeling became a pre-
dominant process after 6 weeks of age, indicating that
osteoblasts were unable to fully replace resorbed bone.
Alteration of osteoblast-mediated bone formation in
absence of p38a was further supported by in vitro analyses.
In cultures, Cre-mediated deletion of p38a occurred when
Dp38a osteoblasts stopped proliferating and started to
differentiate. In addition, inhibition of p38a MAPK with a
selective inhibitor during the proliferation phase of wild-
Fig. 5 Osteoblast-specific
disruption of p38a does not
affect bone resorption. a Real-
time PCR analyses of Rankl and
Opg expression in femurs of
12-week-old female p38af/f and
Dp38a mice. b Detection of
TRAP5b in serum of 12-week-
old female p38af/f and Dp38a
mice by ELISA.
c, d Quantitative
histomorphometric
measurements were performed
on the spongiosa at distal
femurs of 12-week-old female
p38af/f and Dp38a mice.
c OcS/BS osteoclast surface/
bone surface; d OcN/BPm
osteoclast number/bone
perimeter. n = 6 per group in
each experiment
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type osteoblasts did not influence cell number (Fig. 6e).
Those results were consistent with unchanged osteoblast
number in Dp38a mutant mice (Fig. 4c, d). Moreover,
osteoblasts lacking p38a were less active than control
osteoblasts as shown by reduced ALP activity, decreased
expressions of Col1a1, Alp, Opn and Ocn, and suppressed
mineralization in vitro (Fig. 6). It is interesting to note that
lack of p38a in osteoblasts exclusively impaired bone
formation at sites of intense remodeling (trabecular and
endosteal surfaces; Table 1), suggesting that p38a could be
a necessary pathway in osteoblasts to couple bone forma-
tion to resorption. One proposed coupling mechanism is the
local release of factors such as TGFb1, BMP2, or IGF1 by
resorption [1]. This hypothesis was further supported by
our experiments in which osteoblasts treated with a selec-
tive inhibitor of p38a were unable to respond to osteogenic
ligands such as TGFb1 and BMP2 (Fig. 6f; supplementary
Fig. S3b).
The age-dependent decrease in bone mass induced by
osteoblast-specific deletion of p38a supports previous
observations of Whitehouse et al. [14] in their homozygous
truncated Nbr1 (trNbr1) mutant mice. Genetic truncation of
Nbr1, a receptor for selective autophagosomal degradation
of ubiquitinated target proteins, was shown to induce an
age-dependent increase in bone mass due to stimulated
bone formation. Unlike the full-length protein, trNbr1
could not bind activated p38 MAPK and target it for
degradation. In cultures, trNbr1 osteoblasts were highly
active and had elevated activation of p38 MAPK. The
pharmacological inhibition of p38 MAPK could abrogate
the increased trNbr1 osteoblast activity [14]. Interestingly,
the bone phenotype of our Dp38a mutant mice was the
opposite to that of trNbr1 mutant mice.
In conclusion, this report shows that the osteoblast-
specific disruption of p38a leads to a progressive decline of
postnatal bone mass due to defective osteoblast function. It
clearly demonstrates that the p38a MAPK is a critical
positive regulator of postnatal osteoblastic bone formation.
It has been previously reported that the p38a MAPK
pathway controls inflammatory cytokine production by T
cells and osteoclast differentiation [36] and that selective
p38a inhibitors can prevent osteoclast-mediated
Fig. 6 Osteoblasts lacking
p38a exhibit a defective
function in vitro. a–d Primary
osteoblasts were isolated from
the long bones of p38af/f and
Dp38a mice and their
phenotypes were compared.
a Osteoblast marker gene
expression was assessed by real-
time PCR after 7 days of culture
in osteogenic medium. b Alp
activity was measured after
10 days of culture in osteogenic
medium. c Representative
images and d quantification of
matrix mineralization evaluated
by Alizarin Red-S (AR-S)
staining after 21 days of culture.
e, f Primary osteoblasts were
isolated from wild type mice
and cultured in the absence
(vehicle: DMSO) or presence of
SD282, a selective p38a
inhibitor. e Cell number was
measured by counting cells
cultured for 7 days in the
absence or presence of 10 lM
SD282. f Alp activity was
measured in osteoblasts co-
treated with different doses of
SD282 and vehicle, TGFb1
(5 ng/mL) or BMP2 (50 ng/mL)
for 4 days. **p B 0.01
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inflammatory osteolysis [37] and bone loss induced by
estrogen deficiency [38]. However, from our observations,
the long-term use of selective p38a inhibitors may cause
bone tissue deterioration and therefore may not be appro-
priate to treat osteoclast-mediated bone loss.
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